Investment Rating - The report maintains a "Buy" rating for the company [9] Core Insights - The company's performance met expectations, with a projected revenue of 260 million yuan for 2025, despite a year-on-year decline of 26.36% in revenue and a significant drop in net profit [2][6] - Domestic business is expected to reach a turning point, while overseas operations continue to expand [2] - The company has launched new products, including the AQ-400, which is anticipated to enhance revenue streams [6] Summary by Sections Financial Performance - In the first half of 2025, the company reported a revenue of 260 million yuan, a decrease of 26.36% year-on-year, and a net profit attributable to shareholders of -40.76 million yuan, down 820.03% [6] - The second quarter of 2025 saw a revenue of 137 million yuan, reflecting a year-on-year decline of 25.84% [6] Domestic and International Business - The domestic business has experienced a decline, attributed to adjustments in business development pace in line with product iteration and market demand [2] - The company has conducted 16 grassroots training events across 11 provinces and 13 cities in China to support standardized grassroots diagnosis and treatment models [2] - The company has established multiple marketing support centers overseas, enhancing its international presence in countries like Germany, the UK, South Korea, and Thailand [2] Research and Development - The company invested 73.81 million yuan in R&D in the first half of 2025, accounting for 28.35% of its revenue, showcasing its innovation capabilities in optical imaging and electronic endoscope manufacturing [6] - New product launches include the dual-channel endoscope and the 60 series of digestive endoscopes, which have improved product competitiveness [6] Future Outlook - The report projects net profits attributable to shareholders for 2025, 2026, and 2027 to be 110 million, 490 million, and 1.4 billion yuan respectively, indicating a positive growth trajectory [6]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Insights - In the first half of 2025, the company achieved a net profit attributable to shareholders of 1.358 billion yuan, representing a year-on-year growth of 24.6%. The operating revenue was 4.355 billion yuan, with R&D expenditure of 548 million yuan, up 15% year-on-year. The adjusted non-operating EBITDA was 1.610 billion yuan [2][4]. - The company entered into a significant collaboration with Pfizer, securing a $1.5 billion upfront payment for the PD-1/VEGF dual antibody SSGJ-707, with 13 pipelines nearing harvest in four major therapeutic areas, indicating strong growth momentum [2][4]. - The company has a diversified product matrix through external collaborations, including a partnership for an oral paclitaxel solution and a collaboration for semaglutide injection for weight loss [4]. Financial Performance - The company reported a net profit of 1.358 billion yuan in H1 2025, a 24.6% increase year-on-year, with operating revenue of 4.355 billion yuan and gross profit of 3.716 billion yuan. R&D spending was 548 million yuan, reflecting a 15% increase [4]. - The company’s cash on hand was nearly 8 billion yuan as of June 30, 2025, and its interest-bearing debt decreased by nearly half, resulting in a leverage ratio drop from 19.7% at the end of 2024 to 9.9% [4]. Pipeline and Collaborations - The company has 30 products in its pipeline, with 13 new drugs advancing to clinical phase III or NDA submission stages. Notable products include PD-1/HER2 dual antibody SSGJ-705 and PD-1/PD-L1 dual antibody SSGJ-706, both in phase II clinical trials [4]. - The collaboration with Pfizer is expected to yield up to $4.8 billion in milestone payments and double-digit sales royalties, enhancing the company's global innovation pipeline [4]. Earnings Forecast - The company’s projected net profits for 2025, 2026, and 2027 are 2.372 billion yuan, 2.696 billion yuan, and 3.138 billion yuan, respectively, with corresponding EPS of 0.98 yuan, 1.11 yuan, and 1.29 yuan [4].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Insights - In August 2025, the company sold 4,260 buses, representing a year-on-year increase of 16.8% and a month-on-month increase of 32.3%. The sales of medium and large buses were 3,623 units, with a year-on-year increase of 15.8% and a month-on-month increase of 44.2% [2][4]. - For the first eight months of 2025, total bus sales reached 29,000 units, up 4.5% year-on-year, while medium and large bus sales were 24,000 units, down 3.0% year-on-year [2][4]. - The company is recognized as a global leader in the bus industry, with strong long-term growth potential and a consistent high dividend payout, highlighting its investment value [2][10]. - The domestic market is experiencing growth in seated buses, supported by the "old-for-new" policy, which is boosting the demand for new energy buses. The overseas market is benefiting from a globalization and high-end strategy, with exports enhancing profitability and supporting continuous performance improvement [10]. Summary by Sections Sales Performance - In August 2025, the company achieved a total bus sales volume of 4,260 units, with significant increases both year-on-year and month-on-month. The medium and large bus segment showed strong performance, contributing to overall sales growth [2][4][10]. Market Strategy - The company is advancing its direct sales and service model to enhance service quality and efficiency. The "old-for-new" policy in the domestic market is expected to further stimulate the bus market recovery. Internationally, the company is expanding its presence with a new factory in Qatar, which is set to begin production by the end of 2025 [10]. Financial Outlook - The company is projected to have a net profit attributable to shareholders of 48.2 billion and 56.2 billion for 2025 and 2026, respectively, with corresponding price-to-earnings ratios of 13.4X and 11.5X [10].

丨证券研究报告丨 公司研究丨点评报告丨海力风电（301155.SZ） [Table_Title] 海力风电：Q2 业绩同比高增，存货历史高位奠 定交付放量基础 报告要点 [Table_Summary] 公司 2025 上半年营业收入 20.3 亿元，同比增长 461.1%；归母净利润 2.1 亿元，同比增长 90.6%；扣非净利润 1.6 亿元，同比增长 61.3%。单季度看，公司 2025Q2 营业收入 15.9 亿 元，同比增长 570.6%；归母净利润 1.4 亿元，同比增长 315.8%；扣非净利润 1.4 亿元，同比 增长 379.9%。 分析师及联系人 [Table_Author] %% %% %% %% research.95579.com 1 邬博华 曹海花 司鸿历 周圣钧 SAC：S0490514040001 SAC：S0490522030001 SAC：S0490520080002 SAC：S0490524120003 SFC：BQK482 SFC：BVD284 请阅读最后评级说明和重要声明 海力风电（301155.SZ） cjzqdt11111 [Table_Title 海力风电：Q22 ...

Investment Rating - The report maintains a "Buy" rating for Qingdao Beer [9] Core Views - Qingdao Beer achieved a total revenue of 20.491 billion yuan in H1 2025, representing a year-on-year increase of 2.11%. The net profit attributable to shareholders was 3.904 billion yuan, up 7.21% year-on-year, while the net profit excluding non-recurring items was 3.632 billion yuan, an increase of 5.99% year-on-year [2][4] - The company’s sales volume reached 4.732 million kiloliters in H1 2025, with a volume increase of 2.3%, outperforming the domestic beer industry, which saw a decline of 0.3% in cumulative production from January to June. The main brand's sales volume increased by 3.9% in H1 2025 [5] - The improvement in gross margin is driven by cost benefits and product structure optimization, with the gross margin rising by 2.09 percentage points year-on-year to 43.7% in H1 2025 [6] Summary by Sections Financial Performance - In Q2 2025, total revenue was 10.046 billion yuan, a year-on-year increase of 1.28%. The net profit attributable to shareholders was 2.194 billion yuan, up 7.32% year-on-year, and the net profit excluding non-recurring items was 2.029 billion yuan, an increase of 6.02% year-on-year [2][4] - The net profit margin for H1 2025 improved by 0.91 percentage points to 19.05%, while the gross margin increased by 2.09 percentage points to 43.7% [6] Market and Product Strategy - The company is focusing on product innovation and has launched several new products, including "light dry," "sakura-flavored white beer," and "hazy IPA," to strengthen its market position across all categories and channels [5] - The revenue in Shandong province grew by 2.56% in H1 2025, contributing significantly to overall growth and profit improvement. The East China region saw a revenue increase of 9.94% with a notable improvement in net profit margin [5] Future Outlook - The company is expected to continue its steady growth in H2 2025, driven by ongoing cost benefits and a trend towards premiumization. The projected net profits for 2025, 2026, and 2027 are 4.91 billion, 5.43 billion, and 6.01 billion yuan, respectively, with corresponding price-to-earnings ratios of 19X, 17X, and 15X [7]

金融工程丨点评报告 丨证券研究报告丨 [Table_Title] 公募基金半年报持仓风格偏好 报告要点 [Table_Summary] 从风格因子的角度分析，2025Q2 公募基金半年报持仓更加偏好高成长高波动的股票，且对流 动性较低和杠杆较高的公司暴露较为谨慎。从持仓宽基指数成分股占比的角度来看，2025Q2 公募基金对小市值股票的偏好有所提升，但是大部分股票仓位仍在大市值股票中。 分析师及联系人 [Table_Author] 覃川桃 杨凯杰 SAC：S0490513030001 SAC：S0490525080004 SFC：BUT353 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 丨证券研究报告丨 cjzqdt11111 2025-09-09 金融工程丨点评报告 [Table_Title2] 公募基金半年报持仓风格偏好 [Table_Summary2] 事件描述 以普通股票型基金、偏股混合型基金、灵活配置型基金和增强指数型基金为基金池，统计这四 类基金产品的年报和半年报中全部持仓的风格偏好。以个股合计持仓市值为权重，对个股风格 因子暴露值加权求和得到公募 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a significant increase in revenue for the first half of 2025, achieving 8.59 billion yuan, a year-on-year growth of 62.8%. However, the net profit attributable to shareholders decreased by 51.5% to 210 million yuan [2][4]. - In Q2 2025, revenue reached 6.41 billion yuan, marking an 80.3% year-on-year increase, while net profit attributable to shareholders surged by 139.2% to 400 million yuan [2][4]. - The company has seen a rapid increase in wind turbine shipments, with 4.72 GW shipped in the first half of 2025, a 44% increase year-on-year, contributing approximately 6.4 billion yuan in revenue [9]. - The company has also accelerated its overseas orders, with new overseas orders exceeding 2 GW and total overseas order value surpassing 10 billion yuan [9]. Summary by Sections Financial Performance - The company achieved a gross margin of approximately 10.6% in the first half of 2025, which is a decline compared to the previous year. The gross margin for the wind turbine business was 4.65%, with overseas sales gross margin exceeding 20% [9]. - The company’s operating expenses ratio was about 11.1%, a decrease of 4.2 percentage points year-on-year, attributed to improved cost control and revenue growth [9]. Business Segments - Wind turbine business revenue was approximately 6.4 billion yuan, a 30% increase year-on-year, while wind power generation revenue fell by 36% to 80 million yuan [9]. - Wind power service revenue increased by 26% to 180 million yuan, and revenue from power station product sales was about 1.83 billion yuan, with new power stations connected totaling 0.46 GW [9]. Future Outlook - The company is expected to see a recovery in gross margins as wind turbine bidding prices stabilize. The third quarter is anticipated to witness improved performance due to the delivery of higher-priced wind turbine orders [9]. - The forecast for the company's net profit attributable to shareholders for 2025 is approximately 1.84 billion yuan, corresponding to a PE ratio of about 18.7 times [9].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company's revenue for the first half of 2025 is 2.19 billion yuan, a year-on-year decrease of 3.1%, while the net profit attributable to the parent company is 50 million yuan, down 75.1% year-on-year [2][4]. - The company is experiencing operational fluctuations due to strategic adjustments, but historical high contract liabilities are expected to lay a foundation for future delivery performance [4][6]. - The company anticipates a recovery in the second half of 2025, driven by the ongoing construction of offshore wind projects and expansion into overseas markets [9]. Revenue Analysis - The revenue breakdown for the first half of 2025 shows: - Wind towers and related products: 810 million yuan, up 33.1% year-on-year - Blade products: 360 million yuan, down 53.8% year-on-year - Offshore engineering products: 210 million yuan, up 124.4% year-on-year - Wind power generation: 690 million yuan, up 4.7% year-on-year - Others: 120 million yuan, up 6.5% year-on-year [9]. Profitability Analysis - The gross margin for the first half of 2025 is approximately 20.9%, a decrease of 5.9 percentage points year-on-year, primarily due to underutilization of production capacity [9]. - The gross margins for specific segments are: - Wind towers and related products: 3.9%, down 4.3 percentage points - Blade products: -14.0%, down 24.2 percentage points - Offshore engineering products: -3.9%, down 14.0 percentage points - Wind power generation: 65.5%, down 1.1 percentage points - Others: 26.3%, up 4.2 percentage points [9]. Future Outlook - The company expects net profit attributable to the parent company to be around 400 million yuan for 2025, corresponding to a PE ratio of approximately 32 times [9].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a revenue of 5.76 billion yuan for the first half of 2025, representing a year-on-year increase of 20.5%. However, the net profit attributable to the parent company was a loss of 93 million yuan, and the net profit after deducting non-recurring items was a loss of 95 million yuan [2][4]. - In Q2 2025, the company achieved a revenue of 3.03 billion yuan, which is a year-on-year increase of 23.6% and a quarter-on-quarter increase of 11.2%. The net profit attributable to the parent company was a loss of 119 million yuan, with a net profit after deducting non-recurring items also showing a loss of 124 million yuan [2][4]. - The company's membrane business revenue reached 5.09 billion yuan, accounting for 88.39% of total revenue, with a year-on-year growth of 23%. The gross margin for the membrane business was 13.5%, down 5.6 percentage points year-on-year due to price declines and narrowing single-unit gross margins [9]. - The company is actively expanding its solid-state battery business, with significant progress in projects related to sulfide solid electrolytes and lithium sulfide, which may enhance profitability in the future [9]. Summary by Sections Financial Performance - For the first half of 2025, the company reported total revenue of 5.76 billion yuan, a 20.5% increase year-on-year, while the net profit attributable to the parent company was a loss of 93 million yuan [2][4]. - In Q2 2025, the revenue was 3.03 billion yuan, reflecting a 23.6% year-on-year increase and an 11.2% quarter-on-quarter increase, with a net loss of 119 million yuan [2][4]. Business Segments - The membrane business generated 5.09 billion yuan in revenue, representing 88.39% of total revenue, with a year-on-year growth of 23%. The gross margin for this segment was 13.5%, down from the previous year due to competitive pricing pressures [9]. - The company’s overseas business is expanding, with direct export revenue of 1.15 billion yuan, accounting for approximately 20% of total revenue [9]. Future Outlook - The company is expected to maintain positive growth in shipments throughout the year, with current prices stabilizing and an improved shipment structure anticipated to enhance profitability [9]. - The solid-state battery business is a key focus, with ongoing projects that may lead to significant advancements in production capabilities and profitability [9].

Investment Rating - The investment rating for the company is "Accumulate" and maintained [9]. Core Views - The company reported total revenue of 4.773 billion yuan and a net profit attributable to shareholders of 87 million yuan for the first half of 2025, reflecting a year-on-year decline of 4% and 8% respectively. In Q2 2025, total revenue was 2.561 billion yuan, with a net profit of 39 million yuan, showing a year-on-year decrease of 9% and 15% respectively [2][6]. Summary by Sections Financial Performance - In H1 2025, the company's B2B business revenue was 4.756 billion yuan, down 4% year-on-year, accounting for 99.64% of total revenue. The gross margin was 9.04%, a decrease of 0.6 percentage points year-on-year, with a net profit of 85 million yuan, down 41% year-on-year [11]. - The company's Q2 performance was impacted by a slowdown in procurement from major clients, leading to a decline in revenue and profit margins [11]. - The SAAS business showed signs of recovery, with revenue of 17 million yuan in H1 2025, down 37% year-on-year, but achieving a gross margin of 24.58%, an increase of 15.3 percentage points year-on-year [11]. Business Segments - The B2B business is focusing on core clients, with over 60% of revenue coming from 100 central enterprises. The company is leveraging AI to enhance efficiency and reduce costs in its procurement services [11]. - The new brand stationery business is expected to contribute positively, with recent collaborations with quality IPs leading to new product launches [11]. Future Outlook - The company anticipates a gradual recovery in revenue and profitability, with projected net profits of 210 million yuan, 250 million yuan, and 310 million yuan for 2025, 2026, and 2027 respectively, corresponding to PE ratios of 24, 20, and 16 [11].